<DOC>
	<DOCNO>NCT00805701</DOCNO>
	<brief_summary>Avodart ( dutasteride ) reduce male hormone ( DHT ) lead prostate growth stimulate cancerous growth . Avodart currently approve FDA treat men symptom enlarge prostate . Avodart work reduce DHT prostate size ; therefore , drug may useful improve low urinary tract symptom ( LUTS ) frequency , urgency , weak stream , urination difficulty ( dysuria ) , among others , men prostate cancer . Avodart may effective men prostate cancer treat hormonal therapy one injection Zolodex ( goserelin ) follow one month later trans-urethral incision prostate ( TUIP ) , three month , seed implantation ( SI ) prostate . The purpose study test whether Avodart ( dutasteride ) effective LUTS dysuria men localize prostate cancer treat single-dose goserelin , TUIP , interval SI .</brief_summary>
	<brief_title>Study Assessing The Efficacy And Safety Of Avodart ( Dutasteride ) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation</brief_title>
	<detailed_description>Dutasteride inhibitor 5 alpha reductase type I type II enzyme convert testosterone DHT , male hormone lead benign prostate growth drive malignant growth . Dutasteride show significantly decrease intraprostatic DHT men localize prostate cancer , additionally cause apoptosis regression prostate cancer [ Andriole , 2004a ; Andriole , 2004b ] . Furthermore , reduction tumor volume also demonstrate human prostate tissue [ Iczkowski , 2004 ] . Dutasteride currently indicate treat symptomatic BPH men enlarge prostate , also study reduce risk prostate cancer men risk ( elevate PSA previous negative biopsy ) . Dutasteride clinically useful improve low urinary tract symptom ( LUTS ) men clinically-localized prostate cancer void difficulty treat single-dose goserelin , TUIP , interval SI . [ Mitcheson , personal observation ] .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Must male ≥35 ≤90 year age 2 . Have biopsy proven , localized prostate cancer 3 . Gleason score ≤ 8 4 . Clinical stage T1cT2b 5 . Serum PSA ( prostate specific antigen ) ≤10ng/mL within 12 month period prior positive prostate biopsy . 6 . Able swallow retain oral medication 7 . Able willing participate full duration study 8 . Able read write ( health outcome questionnaire selfadministered ) , understand instruction relate study procedure give write informed consent . 1 . Subject ever treat prostate cancer follow : Radiotherapy ( external beam brachytherapy ) Chemotherapy Hormonal therapy ( e.g. , megestrol , medroxyprogesterone , cyproterone , diethylstilbestrol ( DES ) Oral glucocorticoid Gonadotropin Releasing Hormone ( GnRH ) analogue ( e.g. , leuprolide , goserelin ) singledose gosereline give treatment study . 2 . Glucocorticoids , except inhaled topical , permit within 3 month prior visit one 3 . Current and/or previous use follow medication : Finasteride ( Proscar , Propecia ) , Dutasteride ( Avodart ) exposure within 6 month prior study entry exclude . Any investigational 5reductase inhibitor within past 12 month . Anabolic steroid ( subject must discontinue 6 month prior study entry eligible ) Drugs antiandrogenic property within past 6 month ( e.g , . spironolactone , flutamide , bicalutamide , *cimetidine , *ketoconazole , progestational agent ) *The use cimetidine permit prior study entry . The use topical ketoconazole permit prior study .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>avodart</keyword>
	<keyword>dutasteride</keyword>
	<keyword>mitcheson</keyword>
</DOC>